79 / 84
79
50. van der Heijde DM, Revicki DA, Gooch KL,
Wong RL, Kupper H, Harnam N, et al. Physical
function, disease activity, and health-related
quality-of-life outcomes after 3 years of adalimumab
treatment in patients with ankylosing spondylitis.
Arthritis Res Ther 2009;11:R124.
51. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ,
Wong RL, Kupper H, et al. Adalimumab
effectiveness for the treatment of ankylosing
spondylitis is maintained for up to 2 years: long-
term results from the ATLAS trial. Ann Rheum Dis
2009;68:922-9.
52. Sieper J, van der Heijde D, Dougados M, Brown
LS, Lavie S, Pangan AL. Early response to
adalimumab predicts long-term remission through 5
years of treatment in patients with ankylosing
spondylitis. Ann Rheum Dis 2012;71:700-6.
53. Inman RD, Davis JC Jr, van der Heijde D,
Diekman L, Sieper J, Kim SI, et al. Efficacy and
safety of golimumab in patients with ankylosing
spondylitis: results of a randomized, double-blind,
placebo-controlled, phase III trial. Arthritis Rheum
2008;58:3402-12.
54. Deodhar A, Braun J, Inman RD, Mack M,
Parasuraman S, Buchanan J, et al. Golimumab
reduces sleep disturbance in patients with active
ankylosing spondylitis: results from a randomized,